VSIG4 and neoplasm: Notably, treatment with anti-VSIG4 antibody or PLX4720 alone exhibited anti-tumor effects, and combination therapy with VSIG4 blockade and BRAFV600E inhibitor synergistically enhanced anti-tumor activity (Fig. S2F-H).